Leerink analyst Faisal Khurshid downgraded aTyr Pharma (ATYR) to Market Perform from Outperform with a price target of $1, down from $16, after the company reported that the Phase 3 EFZO-FIT trial of efzofitimod in pulmonary sarcoidosis failed to meet its primary endpoint. The firm had been positive heading into the “highly binary” readout, but tells investors “we were wrong” after topline results showed no statistically significant difference in steroid reduction. The firm isn’t sure there is a path forward for efzo given the miss on the primary endpoint and unclear clinical relevance of quality-of-life improvement, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATYR:
- aTyr Pharma downgraded to Neutral from Overweight at Cantor Fitzgerald
- Why Is Atyr Pharma Stock Down Today?
- Buy Rating for aTyr Pharma Despite Phase 3 Trial Setback, Focus on Quality of Life Improvements
- Leerink sees low chance of aTyr advancing efzofitimod after miss
- aTyr Pharma Reveals Phase 3 Study Results